Author

Chang Liu

Institutions: Linyi University, Sichuan University, West China Hospital of Sichuan University

Observed institutions: Tongji University, Linyi University, Chinese Academy of Sciences, Sichuan University, West China Hospital of Sichuan University, Center for Excellence in Molecular Cell Science, Shanghai Tenth People's Hospital, University of Chinese Academy of Sciences, State Key Laboratory of Cell Biology

ORCID: 0000-0001-6499-5172

Observed ORCID: 0000-0001-6499-5172

OpenAlex ID: A5023780758

LRCH1 deficiency enhances LAT signalosome formation and CD8 + T cell responses against tumors and pathogens

2020 · Chang Liu, Xiaoyan Xu, et al. · Proceedings of the National Academy of Sciences · 18

Matching-adjusted indirect comparison of tislelizumab plus lenvatinib versus sintilimab plus bevacizumab biosimilar as first-line treatment for unresectable hepatocellular carcinoma

2025 · Kunyuan Wang, Chang Liu, et al. · Frontiers in Immunology · 5

A Chiral Amino Acid-Modified pH-Responsive Nanoplatform Coactivates Cuproptosis and cGAS-STING Signaling Pathways for Cancer Therapy

2025 · Lin Li, Guanheng Wang, et al. · ACS Materials Letters · 5

Recent advances in immunotherapy-involved combination cancer therapy based on ZIF-8

2024 · Guanheng Wang, Lin Li, et al. · AIP Advances · 2

Works count: 4

Citation count: 30

H-index: 3

I10-index: 1